Stratos Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

Stratos Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.3K	Hold	23,000	–	–	﹤0.01%	602
2025 Q4	$78.7K	Buy	23,000 +4,000	+21%	+$17.9K	﹤0.01%	647
2025 Q3	$95.6K	Buy	+19,000	New	+$83.7K	﹤0.01%	667
2025 Q2	–	Sell	-12,000	Closed	-$26.8K	–	670
2025 Q1	$26.8K	Buy	+12,000	New	+$34.4K	﹤0.01%	660
2024 Q4	–	Sell	-45,500	Closed	-$118K	–	712
2024 Q3	$118K	Hold	45,500	–	–	0.01%	716
2024 Q2	$135K	Hold	45,500	–	–	0.01%	680
2024 Q1	$206K	Buy	45,500 +2,000	+5%	+$10.2K	0.01%	626
2023 Q4	$248K	Sell	43,500 -5,000	-10%	-$23.2K	0.01%	593
2023 Q3	$223K	Buy	+48,500	New	+$295K	0.01%	598

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stratos Wealth Advisors's ABCL Position: Q1 2026 in Review

Stratos Wealth Advisors held its AbCellera Biologics (ABCL) position steady in Q1 2026 at 23,000 shares worth $80.3K. The position accounts for ﹤0.01% of the portfolio, ranked #602.

Stratos Wealth Advisors first reported a position in ABCL in Q3 2023 and has held it in 9 quarters since. The position peaked at $248K in Q4 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Stratos Wealth Advisors held 23,000 shares of AbCellera Biologics worth $80.3K as of Q1 2026.
Stratos Wealth Advisors left its AbCellera Biologics share count unchanged in Q1 2026.
AbCellera Biologics made up ﹤0.01% of Stratos Wealth Advisors's portfolio in Q1 2026, its #602 holding.
Stratos Wealth Advisors first reported a position in AbCellera Biologics in Q3 2023 and has held it in 9 quarters since.
Stratos Wealth Advisors's AbCellera Biologics position peaked at $248K in Q4 2023.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.